Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
基本信息
- 批准号:10334499
- 负责人:
- 金额:$ 55.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-02 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntidepressive AgentsAnxiety DisordersBipolar DisorderBirthChildConceptionsConflict (Psychology)Decision MakingDepressive disorderEmotionsEndocrineEventExposure toFathersFemaleFetal DevelopmentFetusGeneral PopulationGeneticGenetic Predisposition to DiseaseGenetic studyGoalsHealthImmuneInvestigationLeadLifeLong-Term EffectsMental DepressionMental HealthMental disordersMood DisordersMoodsMothersOutcomeOutpatientsPerinatalPharmaceutical PreparationsPharmacologyPhysiologyPopulationPostpartum PeriodPregnancyPregnant WomenProcessPsychiatric therapeutic procedureRelapseReportingResidual stateResourcesRiskRisk FactorsSample SizeSamplingSchizophreniaSelf-Injurious BehaviorSeveritiesSiblingsSleep DeprivationSuicideSuicide attemptTimeWomanWorkagedantidepressant effectbasegenetic informationhealth of the motherin uterointerestmaternal depressionmenoffspringperinatal periodperipartum depressionpolygenic risk scorepopulation basedpredictive modelingprenatal exposurerelapse riskreproductivesecondary outcometoolunborn child
项目摘要
Project Summary
Over the past decades, the use of antidepressants (ADs) as first-line treatment for both depressive and anxiety
disorders has increased exponentially, with females in their reproductive years using ADs twice as often as men.
Prior to conception or during pregnancy, approximately 50% of women on ADs (200,000 pregnant women in the
US each year) decide to discontinue their medication. While the wish to avoid in utero AD exposure to the fetus
is understandable, discontinuation of medication might lead to relapse, which can have a profound negative
impact on the health of mother and child. Unfortunately, general information on relapse risks after AD
discontinuation cannot be used during pregnancy and the postpartum period given the enormous changes in
physiology and emotion. Further, women discontinue AD prior to or during pregnancy regardless of their mood
stability, which has an impact on relapse risk. Only three small studies in highly selected populations have
investigated relapse risks during pregnancy and not a single study on AD discontinuation during pregnancy has
investigated the relapse risk postpartum.
This study will quantify the relapse risk during pregnancy and postpartum after AD discontinuation, for
the first time, in a large and representative population sample. We will use the unique Danish national longitudinal
registers covering medication use since 1995 in the entire female population giving birth aged 15-49 years
(N=1,098,137). With our sample size, we will be able to identify both pregnancy specific and non-pregnancy
specific risk factors for relapse and timing to relapse. We will determine to which extent the perinatal period is
different in terms of relapse risks after AD discontinuation compared to other periods in a woman’s life. In
addition, we will explore if women with high genetic susceptibility for mood-disorders are more vulnerable for
relapse after AD discontinuation. In our last aim we will determine the long-term effects (up to 24 years) of
maternal relapse during pregnancy and the postpartum period on the offspring. We will conduct a sibling
comparison, in which we compare the health outcomes in children exposed to maternal relapse to their siblings
not exposed to maternal relapse in the perinatal period. We will explore if polygenic risk scores of the children
influence the association between their exposure to maternal relapse and their long-term psychiatric outcome,
considering in utero exposure to AD medication.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Veerle Bergink其他文献
Veerle Bergink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Veerle Bergink', 18)}}的其他基金
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10296635 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10640239 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10468261 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10569044 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10117285 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
EXPOSURE TO TETRACYCLINE ANTIBIOTICS AND THE POTENTIAL PROTECTIVE EFFECT ON SCHIZOPHRENIA RISK.
接触四环素抗生素及其对精神分裂症风险的潜在保护作用。
- 批准号:
10039207 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
9899554 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
10020516 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
10321798 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别: